NEU 3.50% $14.05 neuren pharmaceuticals limited

I find it annoying that the stock price is the subject of...

  1. 47 Posts.
    lightbulb Created with Sketch. 36
    I find it annoying that the stock price is the subject of continued paper cuts. Pre approval no ROW rights resulted in a reduction from 9 to 7. Post approval, no ROW rights resulted in a drop from 15 to the current price. ROW rights don’t equate to an aggregate $4.625 share price value and reduction, in my humble opinion, and yet it has and here we are. ROW rights announcement are unlikely to recover that loss. I find it hard to fathom that the stock price now is not at least double the pre approval price. Will I sell? Hell no. How does the company hire one or more market makers to eliminate death by paper cut?
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.